Observational studyJournal of gastroenterology and hepatology2026
Gaps in the Cascade of Care Contribute to Poor Liver Cancer Outcomes Among People Living With Hepatitis B: A Multicenter Observational Cohort Study.
Observational study in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundChronic hepatitis B virus (HBV) remains a major cause of hepatocellular carcinoma (HCC) in Australia, despite the availability of effective, subsidized antiviral therapy. We aimed to describe the clinical characteristics, HBV care cascade, and outcomes among people with HBV-related HCC in Victoria, Australia.
methodsWe conducted a multicenter cohort study of all incident HCC cases across eight tertiary health networks in Victoria, Australia. Cases were identified retrospectively (January 1, 2018 to December 31, 2019) and prospectively (January 1, 2020 to October 17, 2022). The primary outcome was the proportion of incident HCC attributable to HBV. Secondary outcomes included uptake of guideline-based antiviral therapy and surveillance and overall survival from HCC diagnosis. Multivariable logistic regression was used to identify factors associated with treatment and surveillance uptake.
resultsAmong 1203 incident HCC cases, 219 (18.2%) were HBV related. Most patients were male (89%) and of Asian ethnicity (60%). While 61% were aged 56-75 years, 25% were 36-55 years. Cirrhosis was present in 141 (64%), although 57 (26%) were newly diagnosed with cirrhosis at HCC presentation. The 121 (60%) patients were eligible for antiviral therapy. Linkage to specialist care was associated with treatment uptake (adjusted OR 8.4, 95% CI 4.3-16.1; p < 0.001). Surveillance enrolment at diagnosis was higher among HBV-related HCC compared with non-HBV HCC (48% vs. 40%).
conclusionHBV remains a substantial contributor to HCC in Australia. Gaps in antiviral treatment and cirrhosis recognition persist, highlighting missed opportunities for prevention and early detection. Interventions to improve linkage to care and delivery of guideline-based HBV management are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.